CINV – Can We Make It a Thing of the Past? - priME Oncology
Webcast
Webcast

CINV – Can We Make It a Thing of the Past?

Not a member of My prIME? Join now for instant access.

Get up-to-date recommendations for chemotherapy- and radiotherapy-induced nausea and vomiting, including guideline-based risk assessment and treatment selection. Our faculty experts provide answers to your toughest questions in supportive care.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CE

CE

1.4 Contact Hours

Release Date

Release Date

Jun 16, 2017

Expiration Date

Jun 16, 2018

Why patients experience nausea and vomiting and what to do about it
Rebecca Clark-Snow, RN, BSN, OCN

Opportunities to avoid CINV in 2017
Charles Loprinzi, MD

The integration of clinical guidelines and personalized medicine to optimize patient care
Rita Wickham, PhD, RN, AOCN

Patient-focused care to help your patients through chemotherapy and radiotherapy
Nicole Edwards, MSN, APN, FNP-BC

Concluding remarks and prIME Points™
Rebecca Clark-Snow, RN, BSN, OCN

CHAIR

  • Rebecca Clark-Snow, RN, BSN, OCNThe University of Kansas Cancer Center
    Westwood, Kansas, United States

FACULTY

  • Nicole Edwards, MSN, APN, FNP-BCWest Cancer Center
    Memphis, Tennessee, United States
  • Charles Loprinzi, MDMayo Clinic
    Rochester, Minnesota, United States
  • Rita Wickham, PhD, RN, AOCNRush University College of Nursing
    Chicago, Illinois, United States

The proposed educational activity is specifically designed to meet the needs of oncology nurses and other healthcare professionals involved in the treatment of patients with CINV.

After successful completion of this educational activity, participants should be able to:

  • Describe the physiologic principles underlying CINV and radiotherapy-induced nausea and vomiting
  • Identify current guideline-based treatments and the unmet medical need for further improvements in CINV management
  • Assess the potential use of a CINV risk factor tool kit to refine treatment and optimize individual patient management
  • Evaluate the most current clinical data on prevention and treatment of CINV, with an emphasis on long-acting neurokinin 1 (NK-1) receptor antagonists

This educational activity is supported by grants from Helsinn Oncology and TESARO, Inc.

Continuing Education

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

A maximum of 1.4 contact hours may be earned for successful completion of this program.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method.  Visit www.oncc.org for complete details on oncology nursing certification.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Clark-Snow has disclosed receipt of fees for participating in advisory or review activities from Merck and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Edwards has disclosed no financial relationships. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Loprinzi has disclosed receipt of research funding provided to Mayo for research trials from Janssen and Bristol Myers Squibb. He also disclosed receipt of fees for participation in advisory or review activities from Mundipharma. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wickham has disclosed receipt of consulting or honorarium fees, payment for lectures, and support for travel to meetings from Genentech. She also disclosed receipt of payment for lectures, support for travel to meetings, and fees for participation in advisory or review activities from Insys Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MBBS, MD, FRCP, FRCPE (medical director content reviewer/planner) – receipt of research funding from Amgen and Bayer
  • Zach Hartman, PhD (scientific content reviewer/planner) – stock or stock options in Advaxis, Inc. and Ariad Pharmaceuticals
  • Brooke Balun, NP (nurse planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.